Trial Profile
Phase IIb, Placebo-Controlled, Randomized, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB) Single Implantation in Tibial Fracture
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 03 Apr 2024
Price :
$35
*
At a glance
- Drugs Allogeneic osteoblastic cell therapy Bone Therapeutics (Primary)
- Indications Fracture
- Focus Proof of concept; Therapeutic Use
- Acronyms ALLOB-TF2
- Sponsors BioSenic
- 03 Jul 2023 According to a BioSenic Media Release, new rules permitted for statistical analysis allowed BioSenic to get the main results of this trial much earlier than anticipated in the original protocol, by this mid-June 2023.
- 22 May 2023 According to BioSenic media release, ALLOB Phase IIb topline results expected by July/August 2023.
- 27 Apr 2023 According to BioSenic media release, ALLOB Phase IIb topline results is foreseen in Q2 2023